Speaker Profile

Ph.D., Emeritus Professor, OHSU

Dr. Joe Gray, a physicist and engineer by training, develops and applies advanced measurement technologies to elucidate mechanisms involved in cancer genesis, progression and response to therapy and he applies systems control strategies to develop more durable and tolerable cancer treatments. His work is described in over 550 publications and 90 US patents. He is a Fellow of the American Association for the Advancement of Science, the American Institute for Medical and Biological Engineering, the American Association of Cancer Research Academy and a member of the National Academy of Medicine. Major awards include the Radiation Research Society Research Award, the E.O. Lawrence Award, United States Department of Energy; Curt Stern Award, American Society for Human Genetics; Brinker Award for Scientific Distinction, Susan G. Komen® Foundation; Simon M. Shubitz Award from the University of Chicago; and Alfred G. Knudson Award Lecture from the National Cancer Institute.

Synergistic Drug Combinations Targeting Tumor and Microenvironment
This presentation describes an implantable microdevice that administers spatially separate nanodoses of multiple agents into a single living tumor and a spatial biology analytical system for analysis of responses tumor and diverse microenvironmental cell types. The resulting analyses identify drug combinations that are highly synergistic when delivered systemically.

 Session Abstract – PMWC 2022 Silicon Valley

Track Chair:
Ira Mellman, Genentech

Human cells have been successfully used as treatment for blood cancers for decades but translating the promise to cell-based treatment for solid tumors has been slow. The advent of gene-editing techniques such as CRISPR, coupled with advances in our understanding of immunology and optimization of growing, manufacturing, transporting, storing, and handling specialized biological samples and materials is transforming the cell therapy field. We will hear in this session about some of the most promising work in the field, as well as the challenges in overcoming resistance

  • Recent Advances in Cell-based Therapy (PANEL)
    Session Chair: Ira Mellman, Genentech
    - Nicholas Haining, ArsenalBio
    - Elliot Norry, Adaptimmune
    - Tina Albertson, Lyell
  • Patentability of Immunotherapies - Latest Developments
    - Janet Xiao, Morrison & Foerster LLP
  • Cell-based Therapy Challenges (PANEL)
    Session Chair: Lawrence Corey, Fred Hutchinson Cancer Research Center
    - Sharon Benzeno, Adaptive Biotechnologies
    - Arati Rao, PACT Pharma
    - Mark Kotter, bit.bio
  • Synergistic Drug Combinations Targeting Tumor and Microenvironment
    - Joe Gray, OHSU
  • Next-generation Supply Chain For Cell & Gene Therapies (PANEL)
    Session Chair: Sharon Benzeno, Adaptive Biotechnologies
    - Amy DuRoss, Vineti
    - Tim Moore, Pact Pharma
  • Biomarkers to Guide Immunotherapy
    Session Chair: Danny Wells, ImmunAI
    - Sanjeev Mariathasan, Genentech
    - Klaus Lindpaintner, InterVenn Bioscience
    - Lou Hawthorne, Nanotics
  • NaNots: A New Class of Immunotherapy
    - Lou Hawthorne, Nanotics
  • Advances in Multi-Omic Spatial Profiling
    Session Chair: Sarah Warren, NanoString Technologies
    - Chris Corless, OHSU
  • Engineered Therapeutics (PANEL)
    Session Chair: Daniel Chen, SITC
    - Kole Roybal, UCSF
    - Paul Parren, Lava Therapeutics
    - Sonja Schrepfer, UCSF